iBio, Inc. (NYSEMKT:IBIO – Get Free Report) shares rose 13.1% during trading on Wednesday . The stock traded as high as $4.37 and last traded at $3.89. Approximately 2,168,577 shares traded hands during trading, an increase of 1,816% from the average daily volume of 113,212 shares. The stock had previously closed at $3.44.
iBio Price Performance
The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.04. The business’s fifty day moving average is $2.96 and its two-hundred day moving average is $2.55.
About iBio
iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.
Featured Articles
- Five stocks we like better than iBio
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 2 Stocks Riding the Dominance of America’s Natural Gas Exports
- 10 Best Airline Stocks to Buy
- Buffett’s on the Sidelines – Should You Follow?
- With Risk Tolerance, One Size Does Not Fit All
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
